Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 56 weeks, less than 100 points in CDAI… compared with adalimumab (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 32‐54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (at 54 weeks) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Clinical relapse · Participants with Crohn's disease in remission
Infliximab combined with purine analogues probably leads to lower clinical relapse (at 48 weeks, CDAI of 150 or greater together with… compared with purine analogues (moderate certainty).
1 finding from 1 review
Loss of clinical response · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether infliximab combined with purine analogues changes withdrawal due to adverse events (at 48 weeks) compared with purine analogues (very low certainty).
1 finding from 1 review
Serious adverse events (at 48 weeks to 2 years) · Participants with Crohn's disease in remission
It is very uncertain whether infliximab combined with purine analogues changes serious adverse events (at 48 weeks to 2 years) compared with purine analogues (very low certainty).
1 finding from 1 review
Clinical relapse · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · Patients with active Crohn's disease
Infliximab 5–10 mg/kg may leads to higher clinical remission defined as CDAI < 150 at week 4 compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Infliximab 5 mg/kg may leads to higher clinical remission at week 26 compared with purine analogues (low certainty).
1 finding from 1 review
Clinical response at week 26 · Patients with active Crohn's disease
Infliximab 5 mg/kg may leads to higher clinical response at week 26 compared with purine analogues (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with purine analogues (low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
It is very uncertain whether infliximab 5 mg/kg changes clinical remission defined as CDAI < 150 at week 4 compared with infliximab 10 mg/kg (very low certainty).
1 finding from 1 review
Induction of 70‐point clinical response CDAI · Patients with active Crohn's disease
It is very uncertain whether infliximab 5 mg/kg changes clinical response defined as reduction in CDAI by 70 points at week 4 compared with infliximab 10 mg/kg (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
Clinical remission defined as absence of any draining fistulas at ≥ 2 consecutive visits, at a median 12 weeks · Patients with active Crohn's disease
It is very uncertain whether infliximab 5 mg/kg changes clinical remission defined as absence of any draining fistulas at ≥… compared with infliximab 10 mg/kg (very low certainty).
1 finding from 1 review
Clinical response defined as reduction of 50% in the number of draining fistula at ≥ 2 consecutive visits, at a median length of time of 12 weeks · Patients with active Crohn's disease
It is very uncertain whether infliximab 5 mg/kg changes clinical response defined as reduction of 50% in the number of… compared with infliximab 10 mg/kg (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
It is very uncertain whether infliximab 5 mg/kg changes clinical remission at week 4 compared with infliximab 20 mg/kg (very low certainty).
1 finding from 1 review